|
시장보고서
상품코드
1863878
요실금 치료제 시장 : 약제 클래스별, 요실금 유형별, 투여 경로별, 성별, 연령층별, 약제 유형별, 최종사용자별, 유통경로별, 지역별Urinary Incontinence Therapeutics Market, By Drug Class, By Incontinence Type, By Route of Administration, By Gender, By Age Group, By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
요실금 치료제 시장은 2025년에 46억 8,000만 달러로 추정되고, 2032년까지 63억 7,000만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR 4.5%로 성장할 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 46억 8,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR | 4.50% | 예측 금액(2032년) | 63억 7,000만 달러 |
세계 요실금 치료제 시장은 전체 의료 산업에서 중요한 부분을 차지하고 있으며, 전 세계 수백만 명의 사람들에게 영향을 미치는 가장 흔하지만 보고가 부족한 의료 질환 중 하나를 다루고 있습니다. 요실금은 방광의 통제력이 의도치 않게 상실되는 증상으로 다양한 연령층에 영향을 미치지만, 해부학적, 생리적 요인으로 인해 주로 노인과 여성에게 영향을 미칩니다. 요실금은 복압성 요실금, 절박성 요실금, 절박성 요실금, 복압성 요실금, 혼합성 요실금 등 여러 가지 유형이 있으며, 각 유형에 따라 다른 치료법이 필요합니다.
본 시장은 항콜린제, 베타3 작용제, 알파차단제 등의 약물요법을 비롯해 의료기기, 수술, 행동치료 등 비약물요법까지 종합적인 치료법을 포괄하고 있습니다. 의료기술의 발전, 혁신적인 약물 제제, 저침습적 치료법의 등장으로 치료 환경은 계속 진화하고 있습니다. 의료진은 요실금이 환자의 삶의 질, 사회적 교류 및 심리적 건강에 미치는 심각한 영향을 점점 더 많이 인식하고 있으며, 효과적인 치료 솔루션에 대한 수요를 촉진하고 있습니다. 의료에 대한 인식이 높아지고, 진단 능력이 향상되고, 치료를 받는 것에 대한 편견이 줄어들고, 신흥 경제국의 의료 인프라가 확충됨에 따라 시장 성장은 더욱 가속화되고 있으며, 이 시장은 현대 의료 제공 시스템의 중요한 구성 요소로 자리매김하고 있습니다.
시장 역학
세계 요실금 치료제 시장은 여러 가지 강력한 요인이 결합하여 확장 궤도를 추진하고 있습니다. 가장 중요한 성장 요인은 고령화 사회로, 노화에 따른 골반저근의 약화, 호르몬 변화, 동반 질환으로 인해 요실금 발생률이 크게 증가하기 때문입니다. 당뇨병, 비만, 신경질환의 유병률 증가도 시장 수요를 더욱 확대시키고 있으며, 이러한 질환은 요실금 발생 위험을 크게 증가시킵니다. 의료 및 환자 지원 단체의 인식 개선 활동의 확대는 사회적 금기를 깨고 더 많은 환자들이 의료 개입을 요청하도록 유도하여 대상 환자 층을 크게 확대하고 있습니다.
약물 전달 시스템의 기술 발전, 유효성 프로파일이 개선된 신약 개발, 최소침습 수술의 도입으로 환자와 의료진 모두에게 매력적인 새로운 치료 패러다임이 만들어지고 있습니다. 그러나 시장에는 눈에 띄는 제약도 존재합니다. 특히 방광 조절 문제를 논의하는 것이 문화적으로 민감한 보수적인 사회에서는 뿌리 깊은 사회적 편견으로 인해 많은 환자들이 치료를 받지 못하는 경우가 많습니다. 많은 지역에서 높은 치료 비용과 제한된 보험 적용 범위는 특히 장기적인 치료 계획에서 접근성에 심각한 장벽이 되고 있습니다. 또한, 항콜린제에 의한 구강건조증, 변비, 인지기능 장애 등 약물 치료에 따른 잠재적 부작용이 환자의 순응도와 치료 도입에 제약이 되고 있습니다.
이러한 과제가 있는 반면, 의료 인프라 개선으로 전문 비뇨기과 의료에 대한 접근성이 확대되고 있는 개발도상국의 미개척 시장에서는 큰 기회가 창출되고 있습니다. 디지털 헬스 기술, 원격 의료 플랫폼, 원격 모니터링 시스템의 통합은 환자 관리와 치료 순응도를 위한 혁신적인 길을 제시하고 있습니다. 또한, 개인 맞춤형 의료 접근법, 바이오마커 발굴, 새로운 치료 표적에 대한 지속적인 연구는 치료 효과에 혁명을 일으키고 새로운 시장 부문을 창출할 수 있는 잠재력을 가지고 있습니다.
본 보고서의 주요 특징
- 세계의 요실금 치료제 시장을 상세하게 분석하고, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 요실금 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기준으로 정리했습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 요실금 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 요실금 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- Porter의 Five Forces 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 요실금 치료제 시장 : 약제 클래스별(2020-2032년)
- 서론
- 무스카린 수용체 길항제(항콜린제)
- B3 아드레날린 수용체 작용제
- 병용요법
- 신경독/신경근 차단제
- 기타 후기 단계 약제
제5장 세계의 요실금 치료제 시장 : 요실금 유형별(2020-2032년)
- 서론
- 임박성/과민성 방광(OAB)/절박성 요실금(UUI)
- 복압성 요실금(SUI)
- 혼합성 요실금(SUI+UUI)
- 일류성 요실금
- 기능성 요실금
- 기타(신경성/배뇨근 과활동)
제6장 세계의 요실금 치료제 시장 : 투여 경로별(2020-2032년)
- 서론
- 경구
- 방광내 주입
- 국소
- 주사제 및 방광내 주사
제7장 세계의 요실금 치료제 시장 : 성별(2020-2032년)
- 서론
- 남성
- 여성
제8장 세계의 요실금 치료제 시장 : 연령층별(2020-2032년)
- 서론
- 성인(19-64세)
- 소아(18세 이하)
- 고령자(65세 이상)
제9장 세계의 요실금 치료제 시장 : 약제 유형별(2020-2032년)
- 서론
- 브랜드
- 제네릭
제10장 세계의 요실금 치료제 시장 : 최종사용자별(2020-2032년)
- 서론
- 병원
- 전문의 및 비뇨기과 클리닉
- 외래수술센터(ASC)
- 홈케어 및 외래 사용
- 장기요양시설
제11장 세계의 요실금 치료제 시장 : 유통 채널별(2020-2032년)
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 요실금 치료제 시장 : 지역별(2020-2032년)
- 서론
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제13장 경쟁 구도
- Astellas Pharma
- Pfizer
- AbbVie
- Merck
- Allergan
- Teva Pharmaceutical
- Janssen
- Reddy's Laboratories
- Endo Pharmaceuticals
- Sumitomo Pharma
- Mylan
- Eli Lilly
- Takeda
- Sanofi
- GlaxoSmithKline
제14장 애널리스트의 제안
- ' Wheel of Fortune '
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제15장 참고 문헌이 및 분석 방법
- 참고 문헌
- 분석 방법
- Coherent Market Insights에 대해
Urinary Incontinence Therapeutics Market is estimated to be valued at USD 4.68 Bn in 2025 and is expected to reach USD 6.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.68 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.50% | 2032 Value Projection: | USD 6.37 Bn |
The global urinary incontinence therapeutics market represents a critical segment within the broader healthcare industry, addressing one of the most prevalent yet underreported medical conditions affecting millions worldwide. Urinary incontinence, characterized by the involuntary loss of bladder control, impacts individuals across various age groups but predominantly affects elderly populations and women due to anatomical and physiological factors. This condition encompasses multiple types including stress incontinence, urge incontinence, overflow incontinence, and mixed incontinence, each requiring distinct therapeutic approaches.
The market encompasses a comprehensive range of treatment modalities including pharmacological interventions such as anticholinergics, beta-3 agonists, and alpha-blockers, alongside non-pharmacological solutions including medical devices, surgical procedures, and behavioral therapies. The therapeutic landscape continues to evolve with advancing medical technologies, innovative drug formulations, and minimally invasive treatment options. Healthcare providers increasingly recognize the significant impact of urinary incontinence on patients' quality of life, social interactions, and psychological well-being, driving demand for effective therapeutic solutions. The market growth is further propelled by rising healthcare awareness, improved diagnostic capabilities, reduced stigma associated with seeking treatment, and expanding healthcare infrastructure in emerging economies, positioning this market as a vital component of modern healthcare delivery systems.
Market Dynamics
The global urinary incontinence therapeutics market is primarily driven by several compelling factors that collectively fuel its expansion trajectory. The aging global population serves as the most significant growth driver, as advanced age correlates strongly with increased incidence of urinary incontinence due to weakened pelvic floor muscles, hormonal changes, and comorbid conditions. Rising prevalence of diabetes, obesity, and neurological disorders further amplifies market demand, as these conditions significantly increase the risk of developing incontinence. Growing awareness campaigns by healthcare organizations and patient advocacy groups are breaking down social taboos and encouraging more individuals to seek medical intervention, substantially expanding the addressable patient population.
Technological advancements in drug delivery systems, development of novel pharmacological agents with improved efficacy profiles, and introduction of minimally invasive surgical procedures are creating new treatment paradigms that attract both patients and healthcare providers. However, the market faces notable restraints including persistent social stigma that prevents many patients from seeking treatment, particularly in conservative societies where discussing bladder control issues remains culturally sensitive. High treatment costs and limited insurance coverage in many regions create significant barriers to access, especially for long-term therapeutic regimens. Additionally, potential side effects associated with pharmacological treatments, such as dry mouth, constipation, and cognitive impairment from anticholinergic medications, limit patient compliance and treatment adoption.
Despite these challenges, substantial opportunities emerge through untapped markets in developing countries where healthcare infrastructure improvements are expanding access to specialized urological care. The integration of digital health technologies, telemedicine platforms, and remote monitoring systems presents innovative avenues for patient management and treatment adherence. Furthermore, ongoing research into personalized medicine approaches, biomarker identification, and novel therapeutic targets promises to revolutionize treatment effectiveness and create new market segments.
Key Features of the Study
- This report provides in-depth analysis of the global urinary incontinence therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global urinary incontinence therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Astellas Pharma, Pfizer, AbbVie, Merck, Allergan, Teva Pharmaceutical, Janssen, Dr. Reddy's Laboratories, Endo Pharmaceuticals, Sumitomo Pharma, Mylan, Eli Lilly, Takeda, Sanofi, and GlaxoSmithKline
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global urinary incontinence therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary incontinence therapeutics market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Muscarinic Receptor Antagonists (Anticholinergics)
- Solifenacin
- Fesoterodine
- Oxybutynin
- Darifenacin
- Tolterodine
- Trospium
- Ba,f-Adrenergic Receptor Agonists
- Mirabegron
- Vibegron
- Combination Therapy
- Mirabegron + Solifenacin
- Neurotoxin/Neuromuscular Blocker
- OnabotulinumtoxinA
- Other Late Phase Drugs
- Incontinence Type Insights (Revenue, USD Bn, 2020 - 2032)
- Urge/Overactive Bladder (OAB)/Urge Urinary Incontinence (UUI)
- Stress Urinary Incontinence (SUI)
- Mixed Urinary Incontinence (SUI + UUI)
- Overflow Urinary Incontinence
- Functional incontinence
- Other (Neurogenic/Detrusor Overactivity)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravesical/bladder instillation
- Topical
- Injectable/intradetrusor
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult (19-64 years)
- Pediatric (<=18 years)
- Geriatric (>=65 years)
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty/Urology clinics
- Ambulatory surgical centers
- Home care/outpatient use
- Long-term care facilities
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Astellas Pharma
- Pfizer
- AbbVie
- Merck
- Allergan
- Teva Pharmaceutical
- Janssen
- Reddy's Laboratories
- Endo Pharmaceuticals
- Sumitomo Pharma
- Mylan
- Eli Lilly
- Takeda
- Sanofi
- GlaxoSmithKline
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Urinary Incontinence Therapeutics Market, By Drug Class
- Global Urinary Incontinence Therapeutics Market, By Incontinence Type
- Global Urinary Incontinence Therapeutics Market, By Route of Administration
- Global Urinary Incontinence Therapeutics Market, By Gender
- Global Urinary Incontinence Therapeutics Market, By Age Group
- Global Urinary Incontinence Therapeutics Market, By Drug Type
- Global Urinary Incontinence Therapeutics Market, By End User
- Global Urinary Incontinence Therapeutics Market, By Distribution Channel
- Global Urinary Incontinence Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Urinary Incontinence Therapeutics Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Muscarinic Receptor Antagonists (Anticholinergics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Solifenacin
- Fesoterodine
- Oxybutynin
- Darifenacin
- Tolterodine
- Trospium
- B3-Adrenergic Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mirabegron
- Vibegron
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mirabegron + Solifenacin
- Neurotoxin/Neuromuscular Blocker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- OnabotulinumtoxinA
- Other Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Urinary Incontinence Therapeutics Market, By Incontinence Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Urge/Overactive Bladder (OAB)/Urge Urinary Incontinence (UUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Stress Urinary Incontinence (SUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Urinary Incontinence (SUI + UUI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Overflow Urinary Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Functional incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other (Neurogenic/Detrusor Overactivity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Urinary Incontinence Therapeutics Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravesical/bladder instillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable/intradetrusor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Urinary Incontinence Therapeutics Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Urinary Incontinence Therapeutics Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult (19-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric (<=18 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric (>=65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Urinary Incontinence Therapeutics Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Urinary Incontinence Therapeutics Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty/Urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory surgical centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home care/outpatient use
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Urinary Incontinence Therapeutics Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Urinary Incontinence Therapeutics Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Incontinence Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
